News
Sarepta Suspends Elevidys Shipments After Pressure From FDA, Hospitals Sarepta's pause on its prescription gene therapy drug for Duchenne muscular dystrophy gives the company time to work with the FDA ...
The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback